Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SENSORCAINE is a local anesthetic combination containing bupivacaine hydrochloride and epinephrine bitartrate, administered by injection. Bupivacaine is a long-acting amide local anesthetic that blocks nerve conduction, while epinephrine acts as a vasoconstrictor to prolong anesthetic effect and reduce systemic absorption. It is used for infiltration, nerve block, and epidural/spinal anesthesia across surgical and pain management settings.
As a mature, approaching-LOE product, the SENSORCAINE brand team is likely focused on lifecycle management and defending market share against generic and branded competitors in a stable but consolidating market.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SENSORCAINE offers experience in mature product management, competitive defense, and healthcare economics in a commoditized therapeutic area. This role is suited for professionals seeking stability and operational efficiency focus rather than launch innovation or rapid growth.
Worked on SENSORCAINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo